A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma

There have been extensive efforts to improve the outcome of glioblastoma, but the prognosis of this disease has not been significantly altered to date. Histone deacetylase inhibitors (HDACIs) have been evaluated as promising anti-cancer drugs and regulate cell growth, cell cycle arrest and apoptosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seung Ah, Kwak, Pil Ae, Park, Chul-Kee, Wang, Kyu-Chang, Phi, Ji Hoon, Lee, Ji Yeoun, Lee, Chang Sik, Lee, Ju-Hee, Kim, Seung-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354719/
https://www.ncbi.nlm.nih.gov/pubmed/27852054
http://dx.doi.org/10.18632/oncotarget.13265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354719/
https://www.ncbi.nlm.nih.gov/pubmed/27852054
http://dx.doi.org/10.18632/oncotarget.13265

Ejemplares similares